Ionis Opening Phase 3 Trial of ION363, Antisense Therapy for FUS-ALS
News
Ionis Pharmaceuticals is opening a Phase 3 safety and efficacy trial of ION363 (jacifusen) in amyotrophic lateral sclerosis (ALS) patients with confirmed mutations in the FUS gene, a known cause of juvenile-onset ... Read more